Skip to main content
Risa Hoffman, MD, Infectious Disease, Los Angeles, CA

RisaMichelleHoffmanMD

Infectious Disease Los Angeles, CA

HIV/AIDS Medicine

Associate Professor, Medicine, University of California Los Angeles David Geffen School of Medicine

Dr. Hoffman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Hoffman's full profile

Already have an account?

  • Office

    757 Westwood Plz
    Los Angeles, CA 90095
    Phone+1 310-206-6766

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Infectious Disease, 2005 - 2008
  • Brigham and Women's Hospital/Children's Hospital/Harvard Medical School
    Brigham and Women's Hospital/Children's Hospital/Harvard Medical SchoolResidency, Internal Medicine/Pediatrics, 2000 - 2005
  • David Geffen School of Medicine at UCLA
    David Geffen School of Medicine at UCLAClass of 2000

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2003 - 2025
  • MA State Medical License
    MA State Medical License 2003 - 2006
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Three Steps to Speedier HIV Med Approvals for Pregnant People
    Three Steps to Speedier HIV Med Approvals for Pregnant PeopleJune 10th, 2021
  • Benefits Outweigh Risks of Dolutegravir for Women of Childbearing Age Living with HIV, Study Shows
    Benefits Outweigh Risks of Dolutegravir for Women of Childbearing Age Living with HIV, Study ShowsApril 3rd, 2019
  • Avoiding Dolutegravir in Young Women with HIV: Time for a Rethink?
    Avoiding Dolutegravir in Young Women with HIV: Time for a Rethink?April 1st, 2019